By Alice Park December 24, 2024 8:00 AM EST P rogress in addressing mental health is notoriously slow and mostly incremental. Breakthrough treatments tend to be rare, and trained professionals too few to meet the demand for services, which is increasing. But 2024 was a pivotal year—thanks to the culmination of decades of research and post-pandemic attention to mental-health issues. In March, the U.S. Food and Drug Administration (FDA) approved Rejoyn, the first digital therapeutic to treat